The chart below compares the forward price to earnings (P/E) ratio of AstraZeneca to multiples in a peer set of leading ...

Wolfe Research initiated coverage of Eli Lilly (LLY) with an Outperform rating and $1,000 price target The company has lost over $100B in ...

The centre will improve the quality of medical research and explore new medicine. Read more at straitstimes.com.

Backed by the Economic Development Board (EDB), the hub was launched on Nov 14 at the Lilly Digital Health and Lilly Centre ...

is a fully owned subsidiary of Eli Lilly & Company. LCCP was established (as Lilly-NUS Centre for Clinical Pharmacology Pte ...

Eli Lilly's tirzepatide cut the risk of developing type 2 diabetes for people with pre-diabetes by 94%, according to new ...

Three stocks that have not only been around for a century but have also been paying dividends for that long are Coca-Cola ...

Has something changed regarding Eli Lilly or Regeneron's thesis, or is the recent dip an excellent opportunity to invest in ...

How can clinical trial participants be prevented from recording information inaccurately? One solution for pharmaceutical ...

The sizeable new round follows the announcement of phase 1 data for its lead asset MET-097i in September and, according to ...

Taking Out OGA. The rationale behind small-molecule OGA inhibition is that these drugs will decrease tau hyperphosphorylation and aggregation into neurofibrillary tangles (right). [Courtesy of Eli ...

Investors continued to see multiple shades of light red as biotechs continued to struggle in the wake of the postelection ...